Original Research

Cost-effectiveness of an atypical conventional antipsychotic in South Africa: An economic evaluation of quetiapine versus haloperidol in the treatment of patients partially responsive to previous antipsychotics

Robin Emsley, Frederik Booysen
South African Journal of Psychiatry | Vol 10, No 3 | a148 | DOI: https://doi.org/10.4102/sajpsychiatry.v10i3.148 | © 2004 Robin Emsley, Frederik Booysen | This work is licensed under CC Attribution 4.0
Submitted: 12 August 2008 | Published: 01 October 2004

About the author(s)

Robin Emsley, Department of Psychiatry, Stellenbosch University, Western Cape, South Africa
Frederik Booysen, Department of Psychiatry, Stellenbosch University, Western Cape

Full Text:

PDF (164KB)


Background. The introduction of a new generation of atypical antipsychotic agents has raised difficult economic and ethical questions, particularly in lower-income countries. The reported tolerability and efficacy advantages of the atypical antipsy- chotics over their conventional predecessors have to be weighed against their higher acquisition costs. Pharmaco-eco- nomic studies conducted in Western countries consistently report cost advantages or cost neutrality for these new agents. However, considerable differences in health care service pro- vision make it difficult to generalise these findings to South Africa.

Method. We compared the direct costs (private and public sector) of treating schizophrenia with an atypical antipsychotic quetiapine, and with a conventional antipsychotic haloperidol, by adapting a decision-analytic pharmaco-economic model for South African circumstances. The sample comprised patients partially responsive to antipsychotics, who had partic- ipated in a multinational randomised controlled trial compar- ing the efficacy and safety of quetiapine versus haloperidol. Results. The estimated total direct cost for the treatment with quetiapine in South Africa was slightly less than for haloperidol for various models in both the private and the public sectors.

Conclusions. Significant differences in health care provision make pharmaco-economic studies conducted in other coun- tries invalid for South African circumstances. Previously queti- apine treatment did not result in direct cost savings in South Africa. However, the recently introduced legislation to estab- lish single exit prices for medications has resulted in the cost of quetiapine treatment declining by 36.7% and that of haloperi- dol by 13%. This has translated into an overall direct cost sav- ing for quetiapine in both the private and public sector models. This, together with additional indirect advantages of the atypi- cal antipsychotics such as improved quality of life and better social and vocational functioning, argues strongly from both an economic and ethical perspective for the use of atypical antipsychotics in treating schizophrenia in South Africa.


No related keywords in the metadata.


Total abstract views: 2969
Total article views: 2528


Crossref Citations

1. Systematic review of pharmacoeconomic models for schizophrenia
Junwen Zhou, Aurélie Millier, Mondher Toumi
Journal of Market Access & Health Policy  vol: 6  issue: 1  first page: 1508272  year: 2018  
doi: 10.1080/20016689.2018.1508272